Targovax ASA
OSE:TRVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Targovax ASA
EPS (Diluted)
Targovax ASA
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Targovax ASA
OSE:TRVX
|
EPS (Diluted)
-kr2
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
EPS (Diluted)
-kr1
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
EPS (Diluted)
kr0
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
EPS (Diluted)
$0
|
CAGR 3-Years
36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Circio Holding ASA
OSE:CRNA
|
EPS (Diluted)
kr0
|
CAGR 3-Years
82%
|
CAGR 5-Years
69%
|
CAGR 10-Years
49%
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
EPS (Diluted)
kr0
|
CAGR 3-Years
67%
|
CAGR 5-Years
53%
|
CAGR 10-Years
26%
|
|
Targovax ASA
Glance View
Targovax ASA is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. The company is headquartered in Lysaker, Akershus and currently employs 22 full-time employees. The company went IPO on 2014-06-16. The firm is developing two complementary and targeted approaches in immuno-oncology: a peptide-based immunotherapy platform for patients with RAS-mutated cancers and a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. The firm's candidate, TG01, is a peptide vaccine that targets mutations in the RAS genes that are associated with cancer, and it is in a phase II clinical trial in pancreatic cancer. The firm's other RAS targeting immunotherapy, TG02 is developed for colorectal cancer treatment. The firm's adenoviral candidate, ONCOS-102 is developed for the treatment of solid tumors, such as melanoma as well as ovarian and prostate cancer.
See Also
What is Targovax ASA's EPS (Diluted)?
EPS (Diluted)
-2.3
NOK
Based on the financial report for Dec 31, 2022, Targovax ASA's EPS (Diluted) amounts to -2.3 NOK.
What is Targovax ASA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 1Y
-109%
Over the last year, the EPS (Diluted) growth was -109%.
